Even so, Glenn Micalizio, a chemist at Scripps, and his colleagues did not develop into considering the compound thanks to its pharmaceutical prospective. Instead, they realized that its advanced carbon skeleton was an ideal target for tests a variety of reaction they had just lately devised.